# Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

> **NCT03895801** · PHASE2 · COMPLETED · sponsor: **InflaRx GmbH** · enrollment: 57 (actual)

## Conditions studied

- Granulomatosis With Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)

## Interventions

- **DRUG:** IFX-1
- **DRUG:** Placebo-IFX-1
- **DRUG:** Glucocorticoid (GC)
- **DRUG:** Placebo-Glucocorticoid (Placebo-GC)

## Key facts

- **NCT ID:** NCT03895801
- **Lead sponsor:** InflaRx GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-03
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-06-08
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895801, "Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03895801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*